Maiwei Biotechnology: Maiwei Jian Injection expands indications and receives supplementary application acceptance.

Maiwei Biosciences announced that its wholly-owned subsidiary Taikang Biotechnology has received the "Acceptance Notice" issued by the National Medical Products Administration, and the supplemental application for Denosumab Injection for the treatment of solid tumor bone metastasis and multiple myeloma has been accepted by the National Medical Products Administration.